XML 31 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
STOCKHOLDERS' EQUITY AND NONCONTROLLING INTERESTS
 9 Months Ended
Jun. 30, 2017
Equity [Abstract]  
STOCKHOLDERS’ EQUITY AND NONCONTROLLING INTERESTS
STOCKHOLDERS’ EQUITY AND NONCONTROLLING INTERESTS
Share Repurchase Program
In November 2016, the VMS Board of Directors authorized the repurchase of an additional 8.0 million shares of VMS common stock commencing on January 1, 2017. Share repurchases under the Company's authorizations may be made in open market purchases, in privately negotiated transactions (including accelerated share repurchase (“ASR”) programs), or under Rule 10b5-1 share repurchase plans, and may be made from time to time in one or more blocks. All shares that were repurchased under the Company's share repurchase programs have been retired. The Company purchased 0.5 million shares of VMS common stock in the three months ended December 30, 2016, under the November 2015 authorization, which expired on December 31, 2016. As of June 30, 2017, approximately 5.5 million shares of VMS common stock remained available for repurchase under the November 2016 authorization.
The Company repurchased shares of VMS common stock under various authorizations during the periods presented as follows:
 
Three Months Ended
 
Nine Months Ended
(In millions, except per share amounts)
June 30,
2017
 
July 1,
2016
 
June 30,
2017
 
July 1,
2016
Number of shares
0.5

 
1.5

 
3.0

 
4.7

Average repurchase price per share
$
93.45

 
$
83.68

 
$
89.68

 
$
80.48

Total cost
$
46.8

 
$
125.5

 
$
269.1

 
$
374.2



Other Comprehensive Earnings
The changes in accumulated other comprehensive loss by component and related tax effects are summarized as follows:
(In millions)
Net Unrealized Gains
(Losses) Defined
Benefit Pension and
Post-Retirement
Benefit Plans
 
Cumulative
Translation
Adjustment
 
Accumulated
Other
Comprehensive
Loss
Balance at September 30, 2016
$
(63.3
)
 
$
(37.5
)
 
$
(100.8
)
Other comprehensive earnings before reclassifications
—

 
4.5

 
4.5

Amounts reclassified out of other comprehensive earnings
2.8

 
—

 
2.8

Tax expense
(0.5
)
 
—

 
(0.5
)
Balance at June 30, 2017
$
(61.0
)
 
$
(33.0
)
 
$
(94.0
)

 (In millions)
Net Unrealized Gains
(Losses) Defined
Benefit Pension and
Post-Retirement
Benefit Plans
 
Net
Unrealized
Gains
(Losses)
Cash Flow
Hedging
Instruments
 
Net
Unrealized
Gains
(Losses)
Available-for-
Sale
Securities
 
Cumulative
Translation
Adjustment
 
Accumulated
Other
Comprehensive Earnings
(Loss)
Balance at October 2, 2015
$
(46.1
)
 
$
—

 
$
(0.1
)
 
$
(40.3
)
 
$
(86.5
)
Other comprehensive earnings (loss) before reclassifications
—

 
(0.9
)
 
(0.4
)
 
0.9

 
(0.4
)
Amounts reclassified out of other comprehensive earnings
1.9

 
0.6

 
0.6

 
—

 
3.1

Tax expense
(0.3
)
 
0.1

 
(0.1
)
 
—

 
(0.3
)
Balance at July 1, 2016
$
(44.5
)
 
$
(0.2
)
 
$
—

 
$
(39.4
)
 
$
(84.1
)

 
The amounts reclassified out of other comprehensive loss into the Condensed Consolidated Statements of Earnings, with line item location, during each period were as follows: 
 
Three Months Ended
 
Nine Months Ended
 
 (In millions)
June 30,
2017
 
July 1,
2016
 
June 30,
2017
 
July 1,
2016
 
Comprehensive Earnings Components
Income (Loss) Before Taxes
 
Income (Loss) Before Taxes
Line Item in Statements of Earnings
Unrealized loss on defined benefit pension and post-retirement benefit plans
$
(0.9
)
 
$
(0.6
)
 
$
(2.8
)
 
$
(1.9
)
Cost of revenues & Operating expenses
Unrealized loss on cash flow hedging instruments
—

 
(0.7
)
 
—

 
(0.6
)
Revenues
Unrealized loss on available-for-sale-investments
—

 
—

 
—

 
(0.6
)
Operating expenses
Total amounts reclassified out of other comprehensive earnings
$
(0.9
)
 
$
(1.3
)
 
$
(2.8
)
 
$
(3.1
)
 
 
Noncontrolling Interests
In connection with the Distribution of Varex in January 2017, the Company's redeemable noncontrolling interests relating to MeVis Medical Solutions AG ("MeVis") were transferred to Varex.

Changes in noncontrolling interests and redeemable noncontrolling interests relating to MeVis and other subsidiaries of the Company were as follows:
 
Nine Months Ended
 
Nine Months Ended
 
June 30, 2017
 
July 1, 2016
 (In millions)
Noncontrolling Interests
 
Redeemable Noncontrolling Interests
 
Noncontrolling Interests
 
Redeemable Noncontrolling Interests
Balance at beginning of period
$
3.7

 
$
10.3

 
$
14.7

 
$
—

Net earnings attributable to noncontrolling interests
0.6

 
0.1

 
(0.2
)
 
0.3

Reclassification of noncontrolling interests in MeVis to redeemable noncontrolling interests
—

 
—

 
(10.4
)
 
10.4

Transfer of redeemable noncontrolling interests in MeVis to Varex
—

 
(10.3
)
 
—

 
—

Other
—

 
(0.1
)
 
(0.5
)
 
(0.4
)
Balance at end of period
$
4.3

 
$
—

 
$
3.6

 
$
10.3